Nasal decongestant sprays are a popular remedy for relieving nasal congestion caused by colds, allergies and sinus infections. These sprays provide quick relief allowing for easier breathing.

"However, research on the underlying mechanism, particularly the role of nasal microbiome, remains limited. In this study, we investigated the associations between olfactory function, the nasal ...

Conducted on fully differentiated human nasal tissue using the MucilAir™ model, the study demonstrated strong local tolerability, a critical benchmark in the product development roadmap.

They had given patients oral supplements of vitamin D to reduce nasal inflammation and reverse the loss of the sense of smell the inflammation often causes. "It helped zero of 28 people," she said.

But the question that you should be asking yourself is whether or not removing nasal hair is safe, and if you must, can it be done without any risks? Dr Sapna Kamalani, Consultant Dermatologist ...

Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades. Yet up to 20% of patients develop early progression after starting ...

Nasal decongestants, often used during cold and allergy seasons, can negatively impact brain health when used long-term or in high doses. Ingredients like pseudoephedrine and phenylephrine ...

Even after nasal polyps are removed, they can continue to cause complications. Here’s how to treat some common problems that can arise. Treating nasal polyps isn’t a one-and-done procedure.

a deep infection of the hair follicle within the nasal vestibule, the area just inside the nostril. Fortunately, it’s fairly easy to treat — but if left untreated, it can lead to rare but life ...

If hands are decolonized to reduce risk of infection, shouldn’t the skin at the nasal vestibule be decolonized, too, especially considering high frequency of hand-to-nose contact? Surprised by ...

Incyte’s previously disclosed phase 3 win in relapsed or refractory follicular lymphoma (R/R FL) sent the company racing to file an expansion bid for its Monjuvi (tafasitamab) by year-end.